UBS Group
MDVL

UBS Group’s MedAvail Holdings, Inc. Common Stock MDVL Stock Holding History

UBS Group’s Portfolio MDVL Stock Details MDVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-133
Closed -$805 – 10284
2023
Q3 		$805 Buy
+133
New +$1.36K ﹤0.01% 8266
2023
Q1 		– Sell
-123
Closed -$1.85K – 10894
2022
Q4 		$1.85K Buy
123
+45
+58% +$1.3K ﹤0.01% 9783
2022
Q3 		$3K Buy
+78
New +$4.48K ﹤0.01% 9631
2022
Q2 		– Sell
-4
Closed – – 11256
2022
Q1 		$0 Sell
4
-195
-98% -$11.7K ﹤0.01% 11171
2021
Q4 		$14K Buy
+199
New +$21.4K ﹤0.01% 8378
2021
Q3 		– Sell
-15
Closed -$9K – 10291
2021
Q2 		$9K Sell
15
-12
-44% -$7.83K ﹤0.01% 8172
2021
Q1 		$19K Sell
27
-31
-53% -$22.3K ﹤0.01% 7449
2020
Q4 		$43K Buy
58
+55
+1,833% +$38.4K ﹤0.01% 6324
2020
Q3 		$3K Buy
3
+1
+50% +$855 ﹤0.01% 7583
2020
Q2 		$1K Sell
2
-3
-60% -$1.76K ﹤0.01% 7826
2020
Q1 		$3K Hold
5
– – ﹤0.01% 7539
2019
Q4 		$4K Buy
5
+4
+400% +$3.4K ﹤0.01% 7692
2019
Q3 		$1K Buy
+1
New +$937 ﹤0.01% 7867
2019
Q2 		– Sell
-8
Closed -$6.57K – 8242
2019
Q1 		$8K Buy
8
+2
+33% +$1.91K ﹤0.01% 6960
2018
Q4 		$5K Buy
+6
New +$4.56K ﹤0.01% 7573
2018
Q3 		– Sell
-5
Closed -$4K – 8352
2018
Q2 		$4K Sell
5
-3
-38% -$2.54K ﹤0.01% 7578
2018
Q1 		$6K Buy
8
+4
+100% +$3.28K ﹤0.01% 7175
2017
Q4 		$3K Sell
4
-1
-20% -$809 ﹤0.01% 7557
2017
Q3 		$4K Buy
+5
New +$4.73K ﹤0.01% 7334
2017
Q2 		– Hold
0
– -$1K – 8073
2017
Q1 		– Sell
-1
Closed -$1.84K – 7484
2016
Q4 		$1K Sell
1
-1
-50% -$898 ﹤0.01% 7660
2016
Q3 		$2K Buy
+2
New +$2.14K ﹤0.01% 7433
2016
Q2 		– Sell
-8
Closed -$8K – 8038
2016
Q1 		$8K Buy
8
+2
+33% +$1.97K ﹤0.01% 6803
2015
Q4 		$6K Buy
+6
New +$8.87K ﹤0.01% 7634
2015
Q3 		– Hold
0
– – – 8710
2015
Q2 		– Hold
0
– – – 8932
2015
Q1 		– Sell
-3
Closed -$11K – 9526
2014
Q4 		$11K Buy
+3
New +$17.4K ﹤0.01% 8334

Other funds holding MDVL

PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AWGLSCP
ABG-WTT Global Life Science Capital Partners Central, Hong Kong, Hong Kong $12.3M AUM 3.13% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CI
Cigna Investments Bloomfield, Connecticut $773M AUM 44.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

UBS Group's MDVL Position: Q4 2023 in Review

UBS Group sold out of MedAvail Holdings, Inc. Common Stock (MDVL) in Q4 2023, closing a stake of 133 shares — an estimated $805 sold.

UBS Group first reported a position in MDVL in Q4 2014 and held it in 24 quarters. The position peaked at $43K in Q4 2020. 21 funds tracked by Wall St. Rank hold MDVL as of Q4 2023.

  • UBS Group reported no remaining MedAvail Holdings, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • UBS Group sold 133 MedAvail Holdings, Inc. Common Stock shares in Q4 2023, an estimated $805.
  • UBS Group first reported a position in MedAvail Holdings, Inc. Common Stock in Q4 2014 and held it in 24 quarters.
  • UBS Group's MedAvail Holdings, Inc. Common Stock position peaked at $43K in Q4 2020.
  • 21 funds tracked by Wall St. Rank held MedAvail Holdings, Inc. Common Stock as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.